[ad_1]
FILE PHOTO: The logo of the US pharmaceutical company Pfizer Inc. is visible at a branch office in Zurich, Switzerland, on October 2, 2018. REUTERS / Arnd Wiegmann
(Reuters) – Pfizer Inc (PFE.N) is in talks to merge its non-patented drug business with Mylan NV (MYL.OSaturday, the Wall Street Journal, quoted people close to the case.
Mylan 's shareholders would receive just over 40% of the new entity, with Pfizer shareholders receiving the rest, the newspaper added, adding that Pfizer would also receive a $ 12 billion product from the company. a new debt sale.
Pfizer and Mylan did not immediately respond to requests for comment.
Report of Maria Ponnezhath in Bengaluru; Edited by Mark Potter
Our standards:The principles of Thomson Reuters Trust.
Source link
